Rockville, MD, United States of America

Hidekazu Shirota


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Hidekazu Shirota

Introduction

Hidekazu Shirota is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented methods. His work focuses on enhancing immune responses to tumors, which is crucial in the fight against various types of cancer.

Latest Patents

Hidekazu Shirota holds a patent for "Compositions and methods for the treatment of cancer." This patent describes methods for inducing an immune response to a tumor in a subject. The methods involve selecting a subject with a tumor and administering a therapeutically effective amount of apoptotic tumor cells conjugated to a CpG oligodeoxynucleotide (ODN). In some embodiments, the CpG ODN is a K-type or a D-type CpG ODN. The patent also outlines methods for treating tumors, including lymphoma, cervical cancer, prostate cancer, breast cancer, colon cancer, and lung cancer.

Career Highlights

Shirota is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution allows him to collaborate with leading experts in the field and contribute to groundbreaking research in cancer treatment.

Collaborations

One of his notable coworkers is Dennis M Klinman, with whom he has likely collaborated on various research projects aimed at improving cancer therapies.

Conclusion

Hidekazu Shirota's innovative approaches to cancer treatment highlight the importance of research and development in the medical field. His patented methods represent a significant advancement in the fight against cancer, showcasing the potential for improved patient outcomes through targeted therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…